Literature DB >> 7930617

Elicitation of specific cytotoxic T cells by immunization with malaria soluble synthetic polypeptides.

U Blum-Tirouvanziam1, C Beghdadi-Rais, M A Roggero, D Valmori, S Bertholet, C Bron, N Fasel, G Corradin.   

Abstract

We have studied the immunogenicity of Plasmodium falciparum circumsporozoite (CS) protein-derived synthetic polypeptides in mice. These synthetic peptides correspond to the N- and the C-terminal domains 22-125 and 289-390, respectively of the P. falciparum 7G8 isolate CS protein expressed on the sporozoite surface. They comprise what is believed to be the mature protein, except for the central repetitive B cell domain. BALB/c (H-2d) mice were immunized s.c. with 50 micrograms soluble CS polypeptides emulsified in IFA. After a single immunization, CS-specific helper and cytotoxic T lymphocytes (CTLs) could be obtained. The resultant CTLs obtained by in vitro restimulation of primed lymph node (LN) cells recognized H-2Kd target cells in the presence of short synthetic peptides defined in the present study. These epitopes are contained within the N- and C-terminal regions of the CS protein, and correspond to sequences 39-47 and 333-342. In addition, these CTLs can specifically lyse H-2d target cells transfected with the CS gene. These results suggest that, by immunization of mice with large soluble CS synthetic polypeptides in IFA, it is possible to obtain MHC class I-restricted T cell responses specific for the CS protein. This approach might be advantageous in the formulation of efficient malaria subunit vaccines.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7930617

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen.

Authors:  Régine Audran; Michel Cachat; Floriana Lurati; Soe Soe; Odile Leroy; Giampietro Corradin; Pierre Druilhe; François Spertini
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

Review 2.  MHC ligands and peptide motifs: first listing.

Authors:  H G Rammensee; T Friede; S Stevanoviíc
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

3.  Plasmodium falciparum synthetic LbL microparticle vaccine elicits protective neutralizing antibody and parasite-specific cellular immune responses.

Authors:  Thomas J Powell; Jie Tang; Mary E Derome; Robert A Mitchell; Andrea Jacobs; Yanhong Deng; Naveen Palath; Edwin Cardenas; James G Boyd; Elizabeth Nardin
Journal:  Vaccine       Date:  2013-02-26       Impact factor: 3.641

4.  Immunogenicity when utilizing adenovirus serotype 4 and 5 vaccines expressing circumsporozoite protein in naïve and adenovirus (Ad5) immune mice.

Authors:  Nathaniel J Schuldt; Yasser A Aldhamen; Sarah Godbehere-Roosa; Sergey S Seregin; Youssef A Kousa; Andrea Amalfitano
Journal:  Malar J       Date:  2012-06-21       Impact factor: 2.979

5.  Protective efficacy of baculovirus dual expression system vaccine expressing Plasmodium falciparum circumsporozoite protein.

Authors:  Mitsuhiro Iyori; Hiroki Nakaya; Katsuya Inagaki; Sathit Pichyangkul; Daisuke S Yamamoto; Masanori Kawasaki; Kyungtak Kwak; Masami Mizukoshi; Yoshihiro Goto; Hiroyuki Matsuoka; Makoto Matsumoto; Shigeto Yoshida
Journal:  PLoS One       Date:  2013-08-12       Impact factor: 3.240

6.  Vaccine platforms combining circumsporozoite protein and potent immune modulators, rEA or EAT-2, paradoxically result in opposing immune responses.

Authors:  Nathaniel J Schuldt; Yasser A Aldhamen; Daniel M Appledorn; Sergey S Seregin; Youssef Kousa; Sarah Godbehere; Andrea Amalfitano
Journal:  PLoS One       Date:  2011-08-30       Impact factor: 3.240

7.  IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice.

Authors:  Robert Schwenk; Margot DeBot; Michael Porter; Jennifer Nikki; Lisa Rein; Roberta Spaccapelo; Andrea Crisanti; Paul D Wightman; Christian F Ockenhouse; Sheetij Dutta
Journal:  PLoS One       Date:  2014-10-24       Impact factor: 3.240

8.  4-1BBL enhances CD8+ T cell responses induced by vectored vaccines in mice but fails to improve immunogenicity in rhesus macaques.

Authors:  Alexandra J Spencer; Julie Furze; Jared D Honeycutt; Alice Calvert; Saroj Saurya; Stefano Colloca; David H Wyllie; Sarah C Gilbert; Migena Bregu; Matthew G Cottingham; Adrian V S Hill
Journal:  PLoS One       Date:  2014-08-20       Impact factor: 3.240

9.  The synthetic Plasmodium falciparum circumsporozoite peptide PfCS102 as a malaria vaccine candidate: a randomized controlled phase I trial.

Authors:  Régine Audran; Floriana Lurati-Ruiz; Blaise Genton; Hildur E Blythman; Opokua Ofori-Anyinam; Christophe Reymond; Giampietro Corradin; François Spertini
Journal:  PLoS One       Date:  2009-10-02       Impact factor: 3.240

10.  Humoral and cell-mediated immunity to MSP3 peptides in adults immunized with MSP3 in malaria endemic area, Burkina Faso.

Authors:  I Nebie; A Diarra; A Ouedraogo; A B Tiono; A T Konate; A Gansane; I Soulama; S Cousens; O Leroy; S B Sirima
Journal:  Parasite Immunol       Date:  2009-08       Impact factor: 2.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.